HOME > TOP STORIES
TOP STORIES
-
BUSINESS Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
-
REGULATORY Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
-
BUSINESS Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
-
BUSINESS Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
-
ORGANIZATION PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
-
BUSINESS Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
-
REGULATORY Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
-
BUSINESS Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
-
REGULATORY Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
-
BUSINESS AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
-
BUSINESS MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
-
REGULATORY Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
-
BUSINESS Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
-
BUSINESS BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
-
REGULATORY Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
-
REGULATORY Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
-
BUSINESS Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
-
BUSINESS Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
-
REGULATORY Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
-
BUSINESS Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
